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The contribution of the cytokine tumor necrosis factor (cachectin; TNF) to host defenses
against staphylococcal foreign body infections was studied in vivo. In tissue cages subcutaneously
implanted into guinea pigs, progressive infection was initiated by a very low inoculum (100 cfu)
of Staphylococcus aureus with a success rate of 100%, as is frequently encountered in related
clinical situations. Locally injected autologous bacterial components derived from the cell wall of
S. aureus, in particular peptidoglycan, were very active in raising TNF levels in tissue cage fluid
and in preventing the development of infection by the 100% infective dose of the test strain.
Furthermore, injection of murine recombinant TNF into tissue cages could substitute for the
bacterial components in preventing experimental infection by S. aureus. The protective effect of
TNF-eliciting bacterial components could be neutralized by anti-TNF antibodies. A local in-
crease in TNF levels might improve host defenses against staphylococcal foreign body infections.
Staphylococcal foreign body infections are a major source
of patient morbidity and implant failure. Not only strains of
Staphylococcus aureus endowed with numerous virulence de-
terminants but also species of coagulase-negative staphylo-
cocci previously considered nonpathogenic are recovered on
infected orthopedic prostheses or cardiovascular devices [I,
2]. Animal models have confirmed the high susceptibility of
artificial implants to low inocula of staphylococci [3-5],
even of weakly virulent strains. These observations con-
firmed the ineffectiveness of local host defense mechanisms
against microorganisms colonizing the implants [2-5].
In a previously developed guinea pig model of foreign
body infection, we have shown that progressive infection was
regularly produced by a very low inoculum (102 cfu) of S.
aureus Wood 46 in subcutaneously implanted tissue cages
[4]. In contrast, the same strain was unable to cause signifi-
cant infection when injected subcutaneously or intraperito-
neally at an inoculum as high as 108 cfu in the absence of
tissue cages [2, 4]. Significant defects in the phagocytic and
bactericidal functions [2, 4, 5] of polymorphonuclear leuko-
cytes were observed in the infected tissue cage fluid, an in-
flammatory exudate elicited by the subcutaneous implant.
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In preliminary observations [6], we have shown that lo-
cally injected bacterial factors obtained from a laboratory
strain of S. aureus could prevent experimental infection by
the same strain. A number of recent studies [7-20] have
shown that host production of cytokines by either nonim-
mune cells (fibroblasts, endothelial cells) or cells of the im-
mune system [7, 8] significantly contributes to host defense
against various pathogens [9-1 I]. One of the most potent
cytokines is tumor necrosis factor (cachectin: TNF); its pro-
duction by mononuclear phagocytes [7, 12] is strongly stimu-
lated by bacterial endotoxin (lipopolysaccharide [LPS]) from
gram-negative organisms [7, 12, 13] or by either fixed or
heat-killed staphylococcal whole cells [14, 18]. Whereas sev-
eral studies have focused on the pathophysiologic effects of
circulating levels of TNF or othercytokines during gram-
negative and -positive [14] bacteremic infections, none has
reported in detail how cytokine release might contribute to
host defense against staphylococcal infections. Furthermore,
the precise contribution of different cell wall or membrane
components of staphylococci or other gram-positive bacteria
[19, 20] as inducers ofTNF release is not entirely elucidated.
We investigated whether injecting staphylococcal cell wall
components into an experimental model of staphylococcal
foreign body infection could elicit strong local production of
TNF and determined the effects of this increased production
of TNF on host susceptibility to experimental S. aureus in-
fection.
Materials and Methods
Tissue Cage Implantation
Rigid perforated polytetrafluoroethylene (Teflon) tubes (in-
ternal and external diameters, 10 and 12 rnm, respectively:
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length, 32 mm) were implanted subcutaneously into guinea pigs
as previously described [4]. Animals were used for further exper-
imentation 3-6 weeks after tissue cage implantation. An impor-
tant characteristic of this model is that the perforations permit
ingress of inflammatory cells into tissue cage fluid, in particular
polymorphonuclear neutrophils and monocytes as previously
described in detail [4].
Preparation of Soluble Bacterial Factors
Crude lysate. One liter of an overnight culture of S. aureus
Wood 46 in Mueller-Hinton broth was washed and suspended
in 10 ml of PBS (GIBCO, Paisley, Scotland). The concentrated
suspension (1011 cells/rnl) was then lysed for 2 h at 37°C with a
mixture of lysostaphin (10 units/ml; Sigma, St. Louis), DNase
(10 ILg/ml; Sigma), and RNAse (10 ILg/ml, Sigma) by a modifica-
tion of a previously published procedure [21]. Thereafter, the
enzymes in the bacterial lysate were inactivated by heating at
90°C for 30 min [21]. The lysate was cleared from particulate
material by two sequential centrifugations at 3000 g for 30 min
and 100,000 g for 60 min, respectively. The protein content of
the solubilized factors ranged from 250 to 520 JLg/ml, as esti-
mated by protein assay (Bio-Rad Laboratories, Munich). Each
preparation was checked for complete heat inactivation of lyso-
staphin activity by showing the absence oflethal effect on expo-
nentially growing test organisms. Accordingly, 106 cfu ofS. aur-
eus Wood 46 was incubated in vitro at 37°C for 60 min in a l-ml
mixture containing 400 JLl of PBS, 250 JLl of tissue cage fluid,
and 250 JLl of either solubilized bacterial factors or PBS as a
control, and viable counts were made at 0 and 60 min.
Partially purified factors. The prophylactically active solu-
ble factors were partially purified from the bacterial lysate by
extraction with an equal volume of 10% trichloroacetic acid
(TCA) for 2 h at 4°C. About 99%of the protein components of
the bacterial lysate were precipitated by TCA and removed by
low-speed centrifugation, as estimated by the Bio-Rad assay.
Thereafter, the TCA-solubilized bacterial components were
concentrated by overnight precipitation at 4°C with 5 vol of
100% ethanol followed by low-speed centrifugation. This eth-
anol precipitate was solubilized in PBS and dialyzed overnight
at 4°C against PBS to remove traces ofTCA, in membrane tub-
ing (Spectrapor; Spectrum, Los Angeles) with a molecular
weight cutoff of 12,000-14,000. Efficient removal of TCA was
assessed by checking the pH of the final solution of partly puri-
fied bacterial factors; a value of 7.2 was usual.
Purified cell walls. Purified cell walls of S. aureus Wood 46
were prepared as described [22]. Briefly, after inactivation of
autolytic enzymes by heat treatment (20 min, 100°C), cells
were disrupted with glass beads and the cell debris separated by
centrifugation for 20 min at 20,000 g. After washing once with
distilled water, membrane residues were removed by treatment
with I% Triton X-IOO for 30 min at 30°C, and the crude cell
wall was thoroughly washed (four times) with distilled water.
Crude cell wall was further depleted of contaminating proteins
by extensive proteolytic digestion with 0.5 mg/rnl trypsin for 16
h at 37°C in 0.05 M phosphate buffer at pH 7.8, washed five
times with distilled water, and lyophilized. Quantitative analysis
of the cell wall preparation was done after hydrolysis with 4 N
HCl for 16 h at 100°C and showed minimal contamination
«5%) by amino acids other than those normally found in pepti-
doglycan [22, 23]. Compared to glutamic acid, the molar ratios
of major cell wall amino sugars and amino acids were 0.98 for
muramic acid, 1.91 for glucosamine, 2.05 for alanine, 1.18 for
lysine, 3.81 for glycine, and 0.16 for serine.
To solubilize prophylactically active components, we incu-
bated a l-mg/ml suspension of purified cell walls with lysosta-
phin, DNase, and RNase as above. After 2 h, the preparation
was also heated for enzyme inactivation as described above, cen-
trifuged at 100,000 g for 60 min to remove unsolubilized mate-
rial, and stored at - 20°e.
Cell wall teichoic acid and peptidoglycan. Ribitol teichoic
acid was purified by extraction of undigested, purified cell walls
(5 rng/rnl) with 10%TCA for 72 h at 4°C, with occasional stir-
ring [24]. After centrifugation at 20,000 g for 20 min at 4°C, the
TCA-solubilized teichoic acid was concentrated by precipitation
with 5 vol ofcold ethanol. After centrifugation, the teichoic acid
precipitate was redissolved in 10% TCA and reprecipitated with
5 vol of cold ethanol, then solubilized in water and lyophilized.
The phosphate content of purified teichoic acid was 300 ILg/mg
as determined by a colorimetric assay [25].
The TCA-insoluble peptidoglycan component of cell walls
was concentrated by centrifugation, then washed repeatedly
with distilled water and lyophilized. Unlike purified teichoic
acid, TCA-purified peptidoglycan had a residual phosphate con-
tent ofonly 30.6 JLg/mg, which indicated a low level ofcontami-
nation by teichoic acid incompletely extracted by TCA. Quanti-
tative analysis of TCA-purified peptidoglycan, after hydrolysis
with 4 N HCl for 16 h at 100°C, showed a shift in the molar ratio
of glucosamine to glutamic acid from 1.98 before TCA extrac-
tion of cell walls to 0.93 after TCA extraction. In addition,
TCA-purified peptidoglycan [25] contained molar ratios of ala-
nine, glycine, lysine, and serine equivalent to those assayed in
purified cell walls [26].
To test the biological properties of teichoic acid-free pepti-
doglycan, we prepared this purified component by an alterna-
tive procedure, namely by releasing ribitol teichoic acid from
undigested, purified cell walls treated. with 60% hydrofluoride
(Riedel-de Haen, Seelze, Germany) as described previously [27,
28]. The phosphorus and ribitol content of peptidoglycan puri-
fied by this procedure was reduced to <5% compared with tryp-
sinized cell walls. Consequently, glucosamine was present in the
amount that corresponds to peptidoglycan. Analysis of the
amino acids and amino sugars clearly indicated that the pepti-
doglycan was not changed by treatment with hydrofluoride.
Screening for Endotoxin and Exotoxin Contamination
Preparations of bacterial components were systematically
screened to exclude significant endotoxin contamination, as as-
sayed by the Limulus amebocyte lysate test (sensitivity, 10 pg/
rnl: Associates of Cape Cod, Woods Hole, MA), and none con-
tained detectable endotoxin. In addition, since recent studies
also showed that a number of staphylococcal exotoxins could
induce TNF production, we had to exclude their contribution in
the preparations. The possible presence ofstaphylococcal enter-
otoxins was investigated by an ELISA (type A-B-C-D; Bommerli
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Laboratories, Bern, Switzerland) according to the manufacturer.
None of these enterotoxins was produced by S. aureus Wood 46
(limit of detection of the test, 0.1-1 ng/ml). Toxic shock syn-
drome toxin (TSST)-I was determined serologically by gel dif-
fusion [29]. Although TSST-I production was demonstrated in
supernatants of S. aureus Wood 46 cultures, this activity was
consistently absent from purified cell walls or their purified com-
ponents. Finally, the presence of staphylococcal a-toxin, of
which S. aureus Wood 46 is a rich producer, was also screened
for by a hemolytic assay against rabbit erythrocytes as previously
described [30]. None of the preparations showed any significant
hemolytic activity.
Experimental Infections and Protection Experiments
S. aureus Wood 46, a protein A-deficient strain, was used as
the infecting microorganism for experimental tissue cage infec-
tion [4, 5]. Occasionally, S. aureus Cowan I, a protein A-rich
strain, or Staphylococcus epidermidis KH II, a clinical isolate
from a catheter-related sepsis [31], were used. Overnight cul-
tures ofbacteria in Mueller-Hinton broth were washed and resus-
pended in 0.9% NaCI. Tissue cages were inoculated with 0.2 ml
of a 10- 7 dilution, which usually contained 0.8-1.2 X 102 cfu/
ml, as checked by plating on Mueller-Hinton agar.
The prophylactic administration ofbacterial components was
done by local inoculation of 0.5 ml (except when indicated) of
the various preparations in 3 of4 tissue cages per animal, at 2-3
h (except when indicated) before inoculation of live S. aureus.
In addition, I tissue cage received 0.5 ml ofsterile nonpyrogenic
saline as a control. Frozen aliquots of enzymatically solubilized
bacterial components, derived from either whole celllysates or
purified cell walls, were thawed just before use.
When purified ribitol teichoic acid or either TCA- or hydro-
fluoride-purified peptidoglycan were tested, they were not enzy-
matically solubilized. Instead, I mg from stored lyophilized prep-
arations was freshly suspended in I ml of PBS by sonication for
15 s with a microsonicator (Branson sonifier 250, Danbury, CT)
before being serially diluted for injection into tissue cages.
Experimental infection or protection was evaluated by quan-
titative bacterial cultures in aspirated tissue cage fluid (minimal
detection level, 10 cfu) [4, 6]. Tissue cage fluid showing no
growth « 10 cfu/ml) at 24 and 48 h after inoculation was scored
as protected [6].
In Vivo Production of TNF
Routinely, a 0.2-ml sample of tissue cage fluid was aspirated
to assay the baseline level of TNF just before prophylactic ad-
ministration of the bacterial components (or control saline) into
tissue cages. At 2 h, a second aspiration was done to assay the
TNF level just before injection of S. aureus Wood 46. TNF
levels were also evaluated after 24 h in tissue cages with culture-
negative fluids. TNF activity in tissue cage fluid samples was
measured using a cytolytic crystal violet assay with actinomycin
D (l ~g/ml)-treated L929 cells (obtained from R. Ulevitch,
Scripps Clinic, San Diego) as described previously [32]. Results
were expressed in units per milliliter, I unit being defined as the
reciprocal ofthe dilution leading to 50%lysis [32]. The reproduc-
Table 1. Prevention of staphylococcal tissue cage infection by
local injection of soluble bacterial components (whole cell lysate)
of S. aureus Wood 46.
No. protected/ Protection rate
Prophylactic substance no. tested (%)
Saline 0/56 0
Whole cell lysate
Untreated 26/26 100
Dialyzed 26/32 91
Partially purified components*
Untreated 16/18 89
Trypsinized! 4/4 100
Digested with proteinase Kt 4/4 100
* Extracted with trichloroacetic acid and ethanol precipitated.
t Incubated with 100 ~g/ml trypsin for 30 min at 37°C followed by
addition of 200 ~g/ml trypsin inhibitor.
t Incubated with I00 ~g/ml proteinase K. followed by heat inactivation of
proteolytic enzyme for 30 min at 90°C.
ibility of the assay was assessed by testing the susceptibility to
lysis of L929 cells by a standard curve of known concentrations
of recombinant murine TNF (rTNF, obtained from B. Allet,
Glaxo, Geneva) (specific activity, 107 units/rnl). Basal levels in
normal tissue cage fluid or serum were <30 units/rnl, which was
taken as the limit ofspecific TNF-induced cytolysis. The specific-
ity of the cytolytic assay ofguinea pig TNF was evaluated by the
neutralizing effect of an anti- TNF mouse monoclonal antibody
(MAb) (2A5 [IgG2a]; provided by D. Degroote, Medgenix,
Fleurus, Belgium). Of many anti-human TNF MAbs, 2A5 was
the only one that cross-reacted with guinea pig TNF, neutraliz-
ing 3-10 cytolytic units in the L929 assay at concentrations of
30-70 ~g/ml.
Results
Prevention ofexperimental foreign body infection by bacte-
rial factors from whole celllysates. In the control group of
guinea pig tissue cages injected with saline, 100% of cages (n
= 56) inoculated with 0.8-1.2 X 102 cfu ofS. aureus Wood
46 developed a permanent infection (table I): Quantitative
cultures ofS. aureus in the tissue cage fluid yielded 104-107
cfu/rnl at either I, 2, or 5 days after inoculation. In contrast,
when 0.5 ml of soluble bacterial factors was injected into
tissue cages 3 h before inoculation, infection was prevented
in all the challenged cages (n = 26, table I). Control experi-
ments verified in vitro that the bacterial lysate per se con-
tained no residual antibacterial activity, as could have re-
sulted from incompletely inactivated lysostaphin. The test
organisms (s. aureus Wood 46) incubated in vitro for 60 min
at 37°C in PBS supplemented with 25% tissue cage fluid
showed an increase in colony-forming unit counts of 97% ±
36% (mean ± SD, n = 6) in the presence ofthe soluble bacte-
rial factors compared with 82% ± 35% in their absence, thus
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Figure 1. Tumor necrosis factor (TNF) concentrations in tissue
cage fluid in guinea pigs (units/rnl), measured 2 h after local injec-
tion of either 0.5 ml of saline, purified cell wall components, or
purified peptidoglycan (PG). Bars indicate median values.
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protective activity was rapidly obtained, since a time lag
ranging from 5 min to 3 h between injection of the solubi-
lized cell wall components and the inoculation of live S.
aureus showed optimal effects (table 2). Furthermore, it ap-
peared that solubilized cell wall components derived from S.
aureus Wood 46 were active not only against infection due to
the autologous strain but also against infection caused by S.
aureus Cowan I or S. epidermidis KH 11 (data not shown).
Three different preparations of chemically purified cell
wall components were also tested in the prophylactic model
of foreign body infection. The least active of these was puri-
fied ribitol teichoic acid. which at 10 J.Lg/ml protected only
30% (n = 10) of the challenged tissue cages (table 2). In
contrast. the most active preparation was TCA-purified pep-
tidoglycan, which at 10 J.Lg/ml protected 100% of the chal-
lenged cages (n = 10). To exclude a major influence of low
levels of teichoic acid. a regular contaminant of TCA-puri-
fied peptidoglycan, we also tested the prophylactic activity of
teichoic acid-free peptidoglycan. prepared by hydrofluoride
treatment of purified cell walls: Injected at 10 J.Lg/ml, it pro-
tected 83% (n = 12) of the challenged tissue cages (table 2).
Prevention oftissue cage infection and in vivo production of
TNF. Analysis ofTNF activity in tissue cage fluid, assayed
by the L929 cytolytic assay, either before or 2 h after injec-
tion of solubilized components from purified cell walls (the
time of inoculation of live S. aureus Wood 46), showed a
dramatic increase in the levels of this cytokine: TNF titers
increased from undetectable before injection to a median of
388 units/rnl (range, 190-20,000; n = 10) at 2 h (figure I).
In contrast, control tissue cage fluids injected with saline
showed no significant increase in TNF titers from before in-
jection to 2 h (figure I). Among the chemically purified cell
.5
u,
Z
to-
Prophylactic substance, time No. protected/ Protection rate
lag before challenge no. tested (%)
Cell wall components
3h 9/11 82
2 h 12/12 100
5 min 9/11 82
Ribitol teichoic acid, 2 h 3/10 30
Peptidoglycan
TCA-purified, 2 h 10/10 100
Hf-purified, 2 h 10/12 83
Table 2. Prevention of staphylococcal tissue cage infection by
local injection of bacterial components enzymatically solubilized
from purified cell walls of S. aureus or chemically purified.
NOTE. 0.5 ml of cell wall components or 10 J-Lg of ribitol teichoic acid
or trichloroacetic acid (TCA)-or hydrofluoride (HF)-purified peptidoglycan
was injected.
demonstrating that lysostaphin had been readily inactivated
by heat treatment.
Early attempts to characterize the physicochemical nature
of the prophylactically active bacterial components showed
that they were not trypsin-sensitive surface components ofS.
aureus Wood 46. because trypsinization of the bacterial cul-
ture. done shortly before cell lysis. left intact the prophylac-
tic activity of soluble components (data not shown). Also.
the prophylactic factors were not low-molecular-weight com-
ponents. since after overnight incubation in membrane tub-
ing with a molecular weight cutoff of 12.000-14.000. un-
dialyzed components were still active for preventing
experimental infection in 91% (n = 32) of challenged tissue
cages (table I). Finally. extraction of soluble components of
the crude lysate with 5%TCA followed by ethanol precipita-
tion produced partially purified bacterial factors still showing
a high prophylactic activity (table I) despite the removal of
--99% of proteins originally present in the lysate superna-
tant. Furthermore, this preparation of partly purified bacte-
rial factors was not altered in its prophylactic activity by
treatment with proteolytic enzymes such as trypsin or pro-
teinase K (table I).
Prevention ofexperimental foreign body infection by solubi-
lized components from purified cell walls. Since the physico-
chemical properties of prophylactic factors derived from
whole celllysates indicated that they were possibly cell wall
components, we also prepared purified cell walls and solubi-
lized their components by the same enzymatic procedure as
described above for whole cell lysis. Control experiments
verified that solubilized components from purified cell wall
contained no residual antibacterial activity, as could have
resulted from incompletely inactivated lysostaphin. nor did
they include any Limulus-detectable endotoxin activity. As
shown in table 2, the solubilized cell wall components were
effective in preventing experimental infection in 88% (n =
34) of tissue cages challenged with S. aureus Wood 46. This
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wall components, the most consistently active inducer of
TNF production in vivo was TCA-purified peptidoglycan,
which at 10 /-Lg/ml increased the median TNF. titers from
<30 to 5250 units/ml (range, 470-15,000; n = 6) in tissue
cage fluid within 2 h (figure 1). Similar results were obtained
with the teichoic acid-free hydrofluoride-purified peptidogly-
can (data not shown). This increase in TNF titers was transi-
tory, since values recorded at 24 h were < 10% of the 2-h
values (not shown).
Prevention of tissue cage infection by purified murine
rTNF. Further experiments were done to evaluate whether
purified murine rTNF could substitute for the solubilized
bacterial factors in preventing tissue cage infection by S. aur-
eus. Initial experiments to determine the optimal quantity
and time lag ofa prophylactic dose of murine rTNF in tissue
cages indicated that 6800 units of the purified cytokine in-
jected 30 min before inoculation of 102 cfu of S. aureus
Wood 46 gave optimal results; in contrast, higher doses
(13,400 and 28,600 units) were poorly effective and possibly
toxic, as suggested by the hemorrhagic aspect of tissue cage
fluids. Experiments in a total of 6 animals confirmed the
good prophylactic effect of 6800 units of murine rTNF,
which prevented tissue cage infection in 73% of the tissue
cages (n = 11) challenged. Because 3400 units was clearly
less effective, protecting only 33%of 6 tissue cages, this regi-
men was not further tested. Control experiments verified
that murine rTNF incubated in vitro with S. aureus Wood 46
exerted no effect on growth or viability of the test strain (data
not shown).
Inhibition of bacterial factor-induced protection by anti-
TNF antibody. To further confirm that protection from ex-
perimental foreign body infection by cell wall components
was mediated by an increase in TNF in tissue cage fluid, we
tried to neutralize this cytokine activity in vivo by anti-TNF
antibodies. A dose of 140 /-Lg of anti-TNF MAb 2A5 (or
isotype-matched MAb without neutralizing activity as a con-
trol) in 0.4 ml of PBS was injected into tissue cages 10 min
before injection ofa protective dose of peptidoglycan. Treat-
ment with 2A5 MAb, but not with control MAb, signifi-
cantly blocked in 6 of 8 tissue cages the peptidoglycan-in-
duced protection against experimental infection with S.
aureus Wood 46 (P < .03, Fisher's exact test with Yates's
correction). Eight control tissue cages injected in parallel
with 10 /-Lg/ml peptidoglycan alone were all protected from
experimental infection with S. aureus.
Discussion
In this report, we showed that staphylococcal cell wall
components consistently prevented locally induced staphylo-
coccal experimental foreign body infection and that a signifi-
cant host response, probably mediated by TNF (cachectin),
was involved in such a prophylactic effect. The relationship
between enhanced resistance to infectious challenge and 10-
cal increase in TNF concentrations was established as fol-
lows: TNF titers increased rapidly (within 2 h) and signifi-
cantly after local injection of the prophylactic bacterial
factors, injection of purified murine rTNF could substitute
for the prophyla,ctic effect of the bacterial factors, and anti-
TNF antibodies in the tissue cage fluid were antagonistic of
the prophylactic effect of bacterial factors.
Our preparations ofprophylactically active staphylococcal
components were screened either by the Limulus assay or by
immunologic and functional assays for the presence of con-
taminating endotoxin or staphylococcal exotoxins, respec-
tively. It was essential to exclude a significant contribution of
these products to the prophylactic effect observed in our
model, because endotoxin [7-13] and several staphylococcal
exotoxins [33-35] are potent in vitro and in vivo inducers of
TNF production and release. Although the staphylococcal
strain used to prepare prophylactic components was an ac-
tive producer of both a-toxin [30] and TSST-l (unpublished
data), neither ofthese exotoxins nor endotoxin could be dem-
onstrated in our preparations of prophylactically active com-
ponents. We assume that staphylococcal exotoxins were ex-
tensively removed from our preparations by the heating and
chemical procedures used.
Attempts to explore at a cellular level by which rnecha-
nism(s) cell wall components ofS. aureus induced TNF pro-
duction in the tissue cage fluid have met with limited success.
In vitro incubation of the most active prophylactic compo-
nents with endotoxin-sensitive murine peritoneal macro-
phages did not show any significant TNF bioactivity (L929
assay), but small amounts of immunoreactive TNF were
found (unpublished data). A possible discrepancy between
TNF levels in vivo and the undetectable to low amounts of
TNF produced by peritoneal macrophages stimulated with
staphylococcal cell wall components could be derived from
the results reported by Burchett et al. [36]. TNF production
by freshly isolated human monocytes is readily stimulated by
LPS. In contrast, the secretion ofTNF in response to LPS of
tissue macrophages was only moderate in the absence of in-
terferon-v, This suggests that the presence of other cells of
the immune system, such as T cells, as producers of IFN-"
may be crucial to elicit the local response in the in vivo
model.
Additional support for the concept of tissue-specific re-
sponsiveness of monocytcs/rnacrophages comes from recent
studies by C. P. Timmerman and A. Fleer (Utrecht, Nether-
lands, personal communication) who demonstrated a signifi-
cant in vitro production of TNF by freshly isolated human
monocytes incubated with purified peptidoglycan. In con-
trast, other studies have shown the absence ofany significant
in vitro TNF production by macrophages incubated with ei-
ther pneumococcal cell surface components [19] or strepto-
coccal peptidoglycan [20]. Finally, other recent reports sug-
gest that lipoteichoic acid from either S. epidermidis [14] or
from streptococci [20] may playa significant role in TNF
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production by mononuclear phagocytes. Therefore, it ap-
pears likely that the presence of macrophages, fibroblasts,
lymphocytes, and polymorphonuclear leukocytes could con-
tribute to local TNF production [7]. A possible target of in-
creased TNF production in tissue cage fluid might well be
polymorphonuclear leukocytes, whose bactericidal activity
was recently shown to be significantly activated by cytokines
released from macrophages and lymphocytes [37].
In conclusion, our experimental model was a useful ap-
proach with which to study localized production ofTNF and
its potential role in host defense against staphylococcal infec-
tions. Further studies should focus on how TNF interacts
with other components of the cytokine network and with
phagocytic cells in vivo and in vitro to better understand
defective host defense mechanisms against staphylococcal
foreign body infections.
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